The FDA has approved satralizumab for adults with thyroid eye disease, introducing the first at-home subcutaneous treatment option. The decision follows two Phase 3 trials, one of which missed its primary endpoint, while the other demonstrated significant improvements in eye bulging and double vision.
The FDA has approved BRYTLY, Alcon's 0.125% apraclonidine eye drops, for temporary relief of redness caused by minor irritation in people aged 12 and older. Alcon claims effects within one minute lasting up to 12 hours, although its longer-duration comparison with Lumify is based on product labeling rather than a disclosed head-to-head trial.
Bausch + Lomb’s Orphia brings AI to cataract education, but adoption will depend on workflow integration, validation, privacy and trust.
Biocon’s new Yesafili studies add switching and subgroup evidence ahead of a planned U.S. launch in the competitive aflibercept market.
Bausch + Lomb is dropping BL1107 eye drops after a Phase 2 glaucoma miss and redirecting the asset toward a geographic atrophy implant.
iHealthScreen Inc. has received U.S. Food and Drug Administration 510(k) clearance for iPredict-DR, an AI-powered Software as a Medical Device for automated diabetic retinopathy screening. The retinal imaging software detects more than mild diabetic retinopathy in adults with diabetes who have not previously been diagnosed with the condition, placing the healthcare AI developer into a
OKYO Pharma’s urcosimod moves toward Phase 3 as the biotech targets neuropathic corneal pain, a severe ocular condition without approved therapy.
Discover how Glaukos’ GLK-321 Phase 2 trial could reshape Demodex blepharitis care through a dropless eyelid-applied treatment.
Find out how Saptalis Pharmaceuticals’ cyclosporine launch could reshape access, competition and generic dry eye treatment.
Find out how Minghui Pharmaceutical’s MHB018A could reshape thyroid eye disease treatment as Phase III trials test its promise.